<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Health-related quality of life in head and neck cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Health-related quality of life in head and neck cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Health-related quality of life in head and neck cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jill Gilbert, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara A Murphy, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Leanne Jackson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bruce E Brockstein, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patricia A Ganz, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Brizel, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marvin P Fried, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H559186636">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Head and neck cancer (HNC) includes those cancers originating in the oral cavity, pharynx (nasopharynx, oropharynx, or hypopharynx), nasal cavity, paranasal sinuses, salivary glands, and larynx.
        </p>
        <p>
         Combined multimodality treatment including surgery, chemotherapy, and radiation has increased disease control for locally advanced HNC. These improvements have come at the expense of increased acute and late effects, which may have a more profound effect on function and quality of life (QOL) than has been previously recognized [
         <a href="#rid1">
          1,2
         </a>
         ]. HNC arises in structurally complex and functionally important areas. Impairment of these areas from both disease and therapy can interfere with basic functions, including eating and speech, and can have a profound effect on social interactions and psychological state [
         <a href="#rid3">
          3
         </a>
         ]. In patients with early-stage human papilloma virus (HPV) associated oropharyngeal squamous cell carcinoma, treatment deintensification is being investigated to improve functional outcomes and reduce toxicity. (See
         <a class="medical medical_review" href="/z/d/html/115014.html" rel="external">
          "Treatment of human papillomavirus associated oropharyngeal cancer", section on 'Is there a role for treatment deintensification?'
         </a>
         .)
        </p>
        <p>
         It is critical for clinicians to have an aggressive systematic approach to prevention and treatment of acute and late treatment effects. In addition, clinicians must be aware of the social, financial, and caregiver issues that may impact long-term QOL. (See
         <a class="medical medical_review" href="/z/d/html/3380.html" rel="external">
          "Overview of treatment for head and neck cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">
          "Management and prevention of complications during initial treatment of head and neck cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H559186642">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         QOL is a broad concept, a subjective, multidimensional, global construct that seeks to provide a comprehensive picture of the patient's perception of himself or herself in the world [
         <a href="#rid4">
          4
         </a>
         ]. The World Health Organization (WHO) defines QOL as an "individual's perception of his or her position in life in the context of the culture and value systems in which the patient lives and in relation to his or her goals, expectations, standards, and concerns" [
         <a href="#rid5">
          5
         </a>
         ]. A fitting description defined QOL as the "perceived discrepancy between the reality of what a person has and the concept of what the person wants, needs, or expects" [
         <a href="#rid6">
          6
         </a>
         ]. In judging the efficacy of treatment, extending survival does not always correlate with improvements in QOL. Conversely, specific treatments may not necessarily prolong life but may enhance its quality. The importance of QOL has been increasingly recognized and is reflected in its use as an outcome measure in cancer research, on par with response rate and survival [
         <a href="#rid4">
          4,7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2833.html" rel="external">
          "Evaluation of health-related quality of life (HRQL) in patients with a serious life-threatening illness", section on 'Measuring HRQL'
         </a>
         .)
        </p>
        <p>
         Health-related QOL (HRQOL) focuses upon the patient's perception of the impact of illness before, during, and after treatment. The fundamental premise of HRQOL includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multidimensionality
         </strong>
         – QOL encompasses a broad range of domains [
         <a href="#rid5">
          5
         </a>
         ]. These include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Physical health (eg, pain, fatigue, sleep)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Psychological (eg, body image, mood, memory, concentration)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Level of independence/function (eg, mobility, activities of daily living, work capacity)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Social (eg, work, personal relationships, sexuality)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Environment (eg, financial resources, transportation resources)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Spirituality/religion/personal beliefs
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subjectivity
         </strong>
         – Different people may have substantially different reactions to a similar illness or disability.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         QOL must be evaluated from the patient's perspective rather than the clinician or caregiver's perspective. The use of a proxy or surrogate may reflect perceptions at odds with those held by the patient [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patient ratings are more sensitive and reliable than those of their clinicians [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         QOL and HRQOL are often used interchangeably in the literature. However, the broad nature of QOL can make it difficult to measure. It is preferable to use HRQOL when discussing the effects of cancer, as HRQOL focuses on the impact of treatment or disease status on QOL. It should also be recognized that QOL is often mistakenly used to indicate symptom burden. While symptom burden may affect QOL, they are not synonymous.
        </p>
        <p class="headingAnchor" id="H559186648">
         <span class="h1">
          RELATIONSHIP BETWEEN SYMPTOMS, FUNCTION IMPAIRMENT, AND QOL
         </span>
         <span class="headingEndMark">
          —
         </span>
         A "symptom" is a perceived alteration in sensation or function. Function loss may be clinically apparent or subclinical. Subclinical function loss may be relevant but may elude capture on patient-reported outcomes. For example, a patient with HNC may have severe silent aspiration that leads to chronic fibrotic lung damage. The impact of symptoms and functional deficits is captured on the physical, functional, and emotional domains of QOL tools. However, symptoms and functional deficits may or may not adversely impact QOL. Thus, symptom burden and functional deficits are not equivalent to QOL. Tools that assess symptom burden and functional deficits cannot be used in place of QOL as a measure of global wellbeing.
        </p>
        <p>
         There are several possible relationships between symptoms or functional deficits and QOL [
         <a href="#rid1">
          1,9
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No correlation between symptom or functional deficits and QOL, regardless of severity or duration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptom intensity or functional deficits increase and QOL decreases with equal inverse proportion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Only intense/severe symptoms or functional deficits affect QOL, while low-intensity symptoms have no impact.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low-intensity/severity symptoms and functional deficits have a notable effect on QOL, but there is a ceiling effect.
        </p>
        <p>
        </p>
        <p>
         In addition, the relationship between QOL and any given level of a specific symptom or functional deficit may assume one of the following trajectories:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Remain stable over time so that for any given level of a symptom or functional deficit, the impact on QOL is unchanged.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient adapts/accommodates to the symptom or functional deficit, and thus, QOL improves despite the fact that the symptom persists unabated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The distress of any given level of a symptom or functional deficit becomes more prominent over time, resulting in decreased QOL.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H559186654">
         <span class="h1">
          SIGNIFICANCE OF QOL MEASURES IN HEAD AND NECK CANCER
         </span>
         <span class="headingEndMark">
          —
         </span>
         QOL measures have several potential applications [
         <a href="#rid1">
          1,8
         </a>
         ]. QOL measurements can:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guide clinical decision-making by identifying patient preferences and treatment goals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Help monitor changes in response to treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Help monitor responses to treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Facilitate communication between the clinician and the patient. Patients may find a QOL scale less intimidating than a face-to-face discussion with the provider, which can save time by directing attention to important issues.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Identify problems that have a significant impact on QOL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Help clinicians prioritize treatment of problems most worrisome to the patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Help train staff to be more responsive to patients' needs and concerns, including patient education services and rehabilitative services.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Help in the development of patient liaison services.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shape public policy and health care decisions made by the government and private institutions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guide the research agendas of pharmaceutical companies and cooperative groups.
        </p>
        <p>
        </p>
        <p>
         As an example, in the randomized controlled Dutch study (CONDOR) of patients with locally advanced HNC treated with induction chemotherapy, both cisplatin-containing chemoradiation (CRT) schedules investigated were not feasible due to poor health-related QOL as well as high symptom scores and toxicity rates [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
         Further details on the treatment approach to induction chemotherapy followed by concurrent CRT in these patients are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">
          "Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy", section on 'Induction chemotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H559186660">
         <span class="h1">
          PITFALLS AND LIMITATIONS OF QOL RESEARCH
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no "gold standard" for measuring QOL [
         <a href="#rid1">
          1
         </a>
         ]. The interpretation of studies of QOL in patients with HNC requires caution, as different instruments measure different symptoms and aspects of QOL. The instrument should be selected carefully for a defined clinical application [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Different studies often employ diverse methodologies and varying assessment instruments, and include patients with different sites and stages of HNC. These issues make comparisons of results between studies difficult or impossible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Baseline data are necessary to attribute a decline in the level of functioning to disease or treatment-related effects. Patients with HNC often have difficulties that are unrelated to their cancer or its treatment but rather are related to comorbidities, including alcohol, tobacco, or other substance abuse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HNC is relatively uncommon, and many studies, thus, have analyzed a relatively heterogeneous patient population with regard to site of cancer within the head and neck region. These differences may influence different domains of QOL, independent of specific treatment effects. Many study samples are too small to provide adequate statistical power for comparisons or analysis by disease site [
         <a href="#rid14">
          14-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Historically, treatment approaches have varied considerably both with respect to modality of treatment (surgery, radiation therapy, and/or chemotherapy) and within modality (eg, type of resection or reconstruction, chemotherapy regimen, or radiation therapy technique). These differences must be taken into consideration when analyzing the impact of treatment on QOL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with more medical needs (eg, advanced tumor stage, recurrent disease, or comorbid disease) might be disproportionately represented as participants in QOL studies, while patients without insurance might be underrepresented [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Tools should take into account the following practical considerations [
         <a href="#rid1">
          1,8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Validity (measure what they say they do)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reliability (reproducible if repeated in the same group)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sensitivity (respond to changes in the patient's condition)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ease of administration (amount of time, manpower, and resources required to collect and analyze data)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient comprehension
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ease of scoring and interpretation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical relevance (ie, changes in score are clinically significant, or meaningful benchmarks exist at which a treatment could be considered to have improved QOL)
        </p>
        <p>
        </p>
        <p>
         Methodological considerations for QOL research study design include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No selection bias
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No floor effect (able to detect worsening of QOL in patients with existing poor QOL)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No ceiling effect (able to detect improvement of QOL in patients with existing good QOL)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Appropriateness across multicultural/multiracial populations
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ease of clinical applicability
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Has an overall global score and domain scores
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multidimensional (see
         <a class="local">
          'Definition'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Self-administered
        </p>
        <p>
        </p>
        <p>
         The choice of tool depends on the study objective, target population, and psychometric properties of the scale [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H559186666">
         <span class="h1">
          PATIENT-REPORTED OUTCOME MEASURES: WHERE DO QOL INSTRUMENTS FIT IN?
         </span>
        </p>
        <p class="headingAnchor" id="H3128257814">
         <span class="h2">
          Available QOL tools
         </span>
         <span class="headingEndMark">
          —
         </span>
         A multitude of patient-reported outcome (PRO) instruments (tools) exist. Such tools are developed for specific purposes and may vary in content and length. QOL measures have been developed largely for use within research environments with the goal of capturing the patient perspective [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Tool selection should be governed by the research question and by the burden to the patient. Lengthy tools have the advantage of providing rich and detailed information regarding the factors contributing to adverse health and QOL-related issues. Conversely, they are associated with increased patient burden. Global single items such as "How is your QOL compared with a year ago?", although general and superficial, offer a quick and easy assessment of QOL and are often used as single items when brief assessments are desired [
         <a href="#rid8">
          8
         </a>
         ]. As an example, in a randomized trial of 110 patients with HNC, nurse-guided screening using the National Comprehensive Cancer Network Distress Thermometer allowed patients the opportunity to discuss problems and challenges, but did not affect patient outcomes such as health-related QOL [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         There are six major categories of tools that are available to assess QOL. Examples of questionnaires for each category are included below  (
         <a class="graphic graphic_table graphicRef96171" href="/z/d/graphic/96171.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,8,23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         General health, which can be used across a range of disease states:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         EuroQOL five dimensions questionnaire (EQ-5D, formally EuroQOL) [
         <a href="#rid24">
          24
         </a>
         ]; Medical Outcomes Study (MOS) short form 36 (SF-36) [
         <a href="#rid25">
          25
         </a>
         ]; Sickness Impact Profile (SIP) [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disease specific, which have been developed specifically for patients with cancer:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The Cancer Rehabilitation Evaluation System (CARES) [
         <a href="#rid28">
          28
         </a>
         ]; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 [
         <a href="#rid29">
          29
         </a>
         ]; Functional Assessment of Cancer Therapy-General (FACT-G) version 4 [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Site specific for HNC patients:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         University of Washington QOL Questionnaire (UWQOL) [
         <a href="#rid31">
          31
         </a>
         ]; EORTC-Head and Neck Quality of Life Questionnaire [
         <a href="#rid32">
          32
         </a>
         ]; FACT-Head and Neck [
         <a href="#rid33">
          33
         </a>
         ]; Performance Status Scale for Head and Neck Cancer Patients; MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) [
         <a href="#rid34">
          34
         </a>
         ]; Vanderbilt Head and Neck Symptom Survey (VHNSS) version 2.0 [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Domain specific:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Voice-related QOL (V-RQOL) [
         <a href="#rid36">
          36
         </a>
         ]; MD Anderson Dysphagia Inventory (MDADI) [
         <a href="#rid37">
          37
         </a>
         ]; Xerostomia Questionnaire (XQ and XQOL) [
         <a href="#rid38">
          38
         </a>
         ]; Shoulder Pain and Disability Index (SPADI) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment specific:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         UWQOL for surgical patients [
         <a href="#rid40">
          40
         </a>
         ]; Head and Neck Radiotherapy Questionnaire (HNRQ) [
         <a href="#rid41">
          41
         </a>
         ]; Quality of Life Radiation Therapy Instrument Head and Neck Module (QOL-RTI/H&amp;N) [
         <a href="#rid42">
          42
         </a>
         ]; Liverpool Oral Rehabilitation Questionnaire [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptom specific:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Brief Fatigue Inventory (BFI) [
         <a href="#rid44">
          44
         </a>
         ]; Brief Pain Inventory-Short Form (BPI-sf) [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1213307270">
         <span class="h2">
          Are QOL tools effective for screening?
         </span>
         <span class="headingEndMark">
          —
         </span>
         There has been an increased interest in screening for symptoms or functional deficits. Studies have demonstrated improved outcomes in the advanced cancer population when screening tools are used to identify such symptoms and functional deficits. In general, screening tools are brief, capture relevant clinical concerns that are actionable, and can be reviewed and interpreted by the clinician at the time of the medical encounter. Screening tools should be tested in the clinic for the ability to improve pertinent clinical outcomes. However, QOL measures are not designed to screen for clinical issues and are not necessarily good screening tools.
        </p>
        <p class="headingAnchor" id="H559186672">
         <span class="h1">
          QOL AND SURVIVAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         For cancer in general, health-related QOL (HRQOL) scores were associated with survival in a systematic review of all English language biomedical journals between 1982 and 2008 [
         <a href="#rid46">
          46
         </a>
         ]. Global QOL, functioning domains, and symptoms scores (including appetite loss, pain, and fatigue) were important indicators, both individually and combined, for predicting survival in cancer patients. This held true after adjusting for demographic factors and known clinical prognostic variables. (See
         <a class="medical medical_review" href="/z/d/html/2833.html" rel="external">
          "Evaluation of health-related quality of life (HRQL) in patients with a serious life-threatening illness"
         </a>
         .)
        </p>
        <p>
         Pretreatment (baseline) QOL data also appeared to be useful in establishing prognostic criteria for treating cancer patients [
         <a href="#rid46">
          46
         </a>
         ]. For example, pretreatment QOL in patients with HNC predicted for survival independent of prognostic factors in a study of 106 patients using both the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and the EORTC Head and Neck Cancer Module [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Results from an additional prospective study using Short Form-36 (SF-36) physical and mental component scores and the Head and Neck QOL scores in 495 HNC patients within two years of their initial diagnosis of HNC at any head and neck site showed [
         <a href="#rid48">
          48
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Outcomes associated with survival:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         SF-36 physical component scores.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Head and Neck QOL scales for pain, eating, and speech domains.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Level of distress as measured by the General Health Questionnaire (GHQ) sum scores predicted survival [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Outcomes not associated with survival:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         SF-36 mental component score.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Head and Neck QOL scale for emotional domain.
        </p>
        <p>
        </p>
        <p>
         There are several possible explanations for why QOL predicts survival:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor QOL may be a surrogate for advanced disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with poor QOL due to high symptom burden and poor functionality may tolerate treatment poorly and receive less than optimal dosing and scheduling of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor QOL may relate to systemic physiologic alterations associated with cancer burden (eg, activation of inflammatory or neuroendocrine systems) [
         <a href="#rid50">
          50-52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         QOL questionnaires identify symptoms (eg, pain, dysphagia, weight loss) that may reflect persistent or recurrent disease [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H559186678">
         <span class="h1">
          PREDICTORS OF QOL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential predictors of QOL during and after treatment include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pretreatment QOL [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient characteristics (eg, age, race, sex, socioeconomic status) [
         <a href="#rid55">
          55,56
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor-related characteristics (eg, primary site, stage) [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment-related characteristics (eg, treatment modality and extent of surgery, adjuvant chemotherapy, radiation therapy) [
         <a href="#rid56">
          56,58
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Health behaviors (eg, smoking, alcohol use) [
         <a href="#rid59">
          59
         </a>
         ]. Smoking cessation may modify declining QOL [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptom burden [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbidities, notably depression [
         <a href="#rid1">
          1,56,57,59,61-63
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Data regarding the impact of these factors on QOL are often mixed. This may be due to methodological differences, including sample size, patient population, tool selection, and time point in treatment trajectory. Alternatively, this may be due to a weak or negligible association between these parameters and QOL. (See
         <a class="local">
          'Pitfalls and limitations of QOL research'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H559186684">
         <span class="h1">
          SPECIFIC SYMPTOMS AND THEIR EFFECT ON QOL
         </span>
        </p>
        <p class="headingAnchor" id="H559186691">
         <span class="h2">
          Disfigurement
         </span>
         <span class="headingEndMark">
          —
         </span>
         HNC or its treatment may result in changes in appearance or disfigurement, with a resultant decline in QOL [
         <a href="#rid64">
          64
         </a>
         ]. This is particularly important with regards to facial features. The face is a highly visible and socially significant body structure in terms of body image as well as for its role in social eating and speech. Cancers involving structures of the face, including the cheeks, lips, eyes, ears, and nose, are particularly susceptible to impaired body image and psychosocial functioning. There appears to be an additive effect of functional impairments that contribute to poorer body image [
         <a href="#rid65">
          65
         </a>
         ]. Conversely, some studies have not found a link between extensive disfiguration and QOL, perhaps as a result of patient adaptation or a perceived trade-off between life/death and disfigurement [
         <a href="#rid66">
          66-68
         </a>
         ]. In one study, even loss of speech and permanent stoma were found to not significantly determine QOL [
         <a href="#rid68">
          68
         </a>
         ]. Psychoeducational intervention programs, including peer counseling and support groups, can help patients better cope with their disease and improve QOL [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         In one study of patients with HNC treated with radiation that used the "Shame and Stigma Scale" (SSS) to evaluate factors that challenged patients' QOL perception, the feeling of regret had the highest impact (39 percent). Social and speech concerns related to HNC were also reported by 17 percent of patients [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H559186697">
         <span class="h2">
          Dysphagia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dysphagia that is present at diagnosis is typically caused by the tumor. Treatment with surgery or radiation may also cause or acutely worsen dysphagia. The degree of dysphagia is dependent on numerous factors, including stage, primary site, and treatment parameters. Unfortunately, dysphagia persists in a significant subset of patients. On average, 50 percent of patients treated with multimodal therapy will suffer from some degree of dysphagia at 6 and 12 months after treatment, with 15 percent having moderate to severe dysphagia [
         <a href="#rid71">
          71
         </a>
         ]. Concomitant administration of chemotherapy with radiation increases the incidence and severity of dysphagia. Regardless of the cause, posttreatment dysphagia influences global QOL and appetite. (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment", section on 'Dysphagia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H559186703">
         <span class="h2">
          Lymphedema
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymphedema is the accumulation of lymphatic fluid in interstitial spaces. Lymphedema secondary to treatment is a common late effect in patients with HNC [
         <a href="#rid72">
          72
         </a>
         ]. External lymphedema commonly involves the neck and submental areas, while internal lymphedema can involve structures such as the larynx and pharynx. Lymphedema is associated with increased symptom burden, decreased functionality, and worse QOL. (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment", section on 'Lymphedema and fibrosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H559186709">
         <span class="h2">
          Voice
         </span>
         <span class="headingEndMark">
          —
         </span>
         Numerous studies have shown that contrary to common assumption, long-term QOL is not decreased after total laryngectomy [
         <a href="#rid73">
          73-75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3394.html" rel="external">
          "Alaryngeal speech rehabilitation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H559186715">
         <span class="h2">
          Xerostomia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Xerostomia is one of the most frequent adverse effects experienced by patients who receive radiation therapy. An inverse relationship between xerostomia and QOL has been observed. Xerostomia, the subjective complaint of dry mouth, more strongly affects QOL than does hyposalivation, the objective finding of decreased salivary flow. This may be explained by the weak correlation between xerostomia and salivary flow. [
         <a href="#rid76">
          76,77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment", section on 'Salivary gland damage and xerostomia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2594813450">
         <span class="h2">
          Systemic symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute illnesses such as infections, trauma, or cancer may result in the production of cytokines, chemokines, and growth factors that serve to modify and coordinate the healing process. In patients who experience an intense or protracted physical insult, these mediators and others yet to be clearly defined may result in harm to the host [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         One of the commonly reported but understudied acute and late effects of cancer and its therapy on systemic symptoms [
         <a href="#rid79">
          79,80
         </a>
         ]. These symptoms were originally described in animal models and were characterized as "sickness behavior" [
         <a href="#rid81">
          81
         </a>
         ]. Systemic symptoms may include fatigue, widespread pain, anxiety, depression, neuropsychiatric symptoms and neurocognitive dysfunction, temperature-related distress and dysregulation, disordered sleep, and gastrointestinal dysfunction. Systemic symptoms often occur in clusters rather than in isolation. In particular, fatigue increases during radiation therapy and is present in 50 to 90 percent of patients with HNC [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         As expected, patients with HNC undergoing active therapy experience profound and severe systemic symptomatology. Of concern, 50 percent of survivors (at least 12 months posttreatment) report at least one systemic symptom. Most patients with systemic symptoms experience multiple symptoms, and in a substantial percentage of affected patients, the symptoms are moderate to severe in intensity. Systemic symptoms are associated with decreased QOL [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H559186721">
         <span class="h1">
          FUNCTIONAL PERFORMANCE AND QOL
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of data from longitudinal studies have shown that impairments in speech, swallowing, and eating do not impair QOL [
         <a href="#rid1">
          1
         </a>
         ]. In spite of residual functional deficits, many patients adapt to their deficits and recover to pretreatment QOL levels. While there are subgroups of patients who continue to experience considerable emotional distress and depression, these symptoms are not clearly related to functional outcome.
        </p>
        <p>
         Non-cancer health events can impact mortality and QOL. For example, lifestyle habits, such as tobacco, marijuana, and alcohol use, have been shown to impact treatment adherence [
         <a href="#rid84">
          84
         </a>
         ]. Body mass index (BMI) &lt;20 kg/m
         <sup>
          2
         </sup>
         , Charlson comorbidity index (CCI) ≥1, and second primary cancers have been shown to impact mortality in advanced HNC [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
         The Veterans Affairs larynx study was a landmark study in which induction chemotherapy plus radiation therapy was found to have equivalent survival rates to total laryngectomy plus postoperative radiation. This study also demonstrated better QOL scores in the induction chemotherapy plus radiation group as opposed to the surgery plus postoperative radiation therapy group. However, regardless of surgical or nonsurgical intervention, the improvement in QOL appeared to be more closely related to freedom from pain, better emotional wellbeing, and lower levels of depression compared with preservation of speech function [
         <a href="#rid86">
          86,87
         </a>
         ]. In fact, numerous studies have shown that long-term QOL is not decreased after total laryngectomy, contrary to common assumption [
         <a href="#rid73">
          73-75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H559186799">
         <span class="h1">
          TRAJECTORY OF QOL AND ITS RELATIONSHIP TO TUMOR AND TUMOR-RELATED FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HNC often have a compromised overall QOL at diagnosis that decreases further during treatment. Typically, overall QOL improves slowly over time such that QOL returns towards baseline by 12 months posttreatment [
         <a href="#rid1">
          1,88,89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">
          "Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer"
         </a>
         .)
        </p>
        <p>
         However, there is a subset of patients, often those with more advanced disease or poor performance status at baseline, whose QOL fails to return to baseline.
        </p>
        <p>
         It is important to note that most QOL tools are composed of subscales, each of which may have multiple items. A substantial percentage of patients may identify problems captured by single items or subscales. These complaints, although substantial, may not be powerful enough to impact overall QOL scores.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a systematic review [
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdocs.google.com%2Fdocument%2Fd%2F1PEy1R9639qG-RpKgjpDdpdg45bt6k4vykatgZoNSSIY%2Fedit%23bookmark%3Did.1hmsyys&amp;token=lYK7f9Or%2Bb887m8ITKgwwYkXVtGfcoWUFGIcEB6zNgzImq8JnJSPNJmgNdJiaTURwGsIvoUPoVKvZfXrHh9muVj5IYYBocuIN85yNsjoqRxCXiMILvlJOQW0rw8WPX90SGJLM%2FcFR3EDrVPaRmVyNg%3D%3D&amp;TOPIC_ID=3369" target="_blank">
          7
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Global QOL deteriorated from the period before treatment to the period one to six months after therapy and then gradually improved until the one-year mark.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The greatest improvements during the first year were in emotional functioning.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The greatest deterioration was in physical functioning at one year.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Most studies in the systematic review showed full recovery of social, cognitive, and role functioning by one year.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most prospective studies have not followed survivors beyond a few years. Data on long-term survivors are limited. Clinical observation and scattered reports support a bimodal impact of treatment on QOL: Patients experience an initial decline in QOL immediately after therapy, followed by a return toward baseline. Years later, patients may experience a decline in QOL associated with late toxicities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study using the Auckland QOL questionnaire in patients with HNC at 10 years following diagnosis found that QOL decreased by an average of 11 percent from QOL prior to treatment; compared with years 1 and 2, QOL decreased by 15 percent [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study, 80 patients with oral or oropharyngeal cancer were followed prospectively. Of these, 26 were evaluated with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and EORTC QLQ Head and Neck 35 at baseline, 6 months, 12 months, and 8 to 11 years. QOL domains significantly worsened (p&lt;0.01) in the long-term included emotional and social functioning, swallowing, speech, taste, smell, dry mouth, sticky saliva, and coughing [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The course of health-related QOL (HRQOL) is different for survivors of HNC versus nonsurvivors, those who will eventually die of their disease. In the first two years after treatment, survivors experienced improvement in HRQOL, while nonsurvivors had no change or deterioration. The exception was emotional functioning, which initially improved after treatment but deteriorated in the long-term for both groups [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H559186805">
         <span class="h1">
          TUMOR-RELATED FACTORS AND THEIR EFFECT ON QOL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data pertaining to the impact of tumor-related factors fail to show a consistent and meaningful impact on QOL. Some general findings are worth noting.
        </p>
        <p class="headingAnchor" id="H94740433">
         <span class="h2">
          Disease site
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral cavity cancers
         </strong>
         – Oral cavity cancers tend to have worse scores for a variety of domains (physical or cognitive functioning, fatigue, appetite, pain, nausea/vomiting, dyspnea, social eating, social contact, mouth opening, and coughing) compared with the other sites [
         <a href="#rid57">
          57,90,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypopharyngeal cancers
         </strong>
         – Patients with hypopharyngeal tumors were found to have suicide rates 12-fold higher than the average population in the United States. Poor emotional support and lack of coping strategies are thought to impact QOL more than functional outcomes [
         <a href="#rid92">
          92
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">
          "Suicidal ideation and behavior in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oropharyngeal cancers
         </strong>
         – Oropharyngeal tumors are recognized as a distinct biological and prognostic subset of HNC. Interest in the effects of treatment on patients with oropharyngeal primaries has increased with the epidemic of human papillomavirus (HPV) associated/p16 positive tumors, although data are limited. (See
         <a class="medical medical_review" href="/z/d/html/115014.html" rel="external">
          "Treatment of human papillomavirus associated oropharyngeal cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H559186746">
         <span class="h2">
          Tumor stage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some studies have found that tumor stage is not significantly associated with any QOL scales [
         <a href="#rid56">
          56,93
         </a>
         ], while other studies reported stage III and IV advanced disease stages were associated with reduced QOL [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with early stage disease at diagnosis have better QOL at one year with regards to eating, appetite, supplement use, role and social functioning, pain, trismus, dry mouth, and financial difficulties [
         <a href="#rid94">
          94,95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Importantly, higher stage disease (T3, T4, N2, or N3) is an indication for more aggressive combined modality treatment, which may result in increased acute and late effects, potentially resulting in reduced QOL. (See
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer"
         </a>
         and
         <a class="local">
          'Impact of treatment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3096199644">
         <span class="h2">
          HPV status
         </span>
         <span class="headingEndMark">
          —
         </span>
         The epidemic of HPV associated oropharyngeal cancers (OPC) has led to a significant paradigm shift in the diagnosis, staging, and treatment of HNC. HPV associated OPC often occurs in patients without a history of smoking or alcohol use. Thus, these patients are less likely to have substantial comorbid disease. Although the average age at diagnosis is only slightly younger than smoking-associated cancers, there is an increased incidence in younger patients. Finally, patients with HPV associated OPC typically have a much better prognosis than those with non-HPV associated OPC. This is reflected in the eighth edition of the American Joint Committee on Cancer (AJCC) staging system, which has delineated separate staging systems for HPV associated and non-HPV associated OPC. (See
         <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">
          "Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          QOL in HPV associated HNC
         </strong>
         –
         <strong>
         </strong>
         Compared with patients with non-HPV associated HNC, patients with HPV associated OPC demonstrate similar QOL trajectories but better overall QOL [
         <a href="#rid96">
          96
         </a>
         ]. Data also indicate that, similar to the general HNC population, patients treated for HPV associated OPC experience an immediate decline in QOL that gradually improves to pretreatment levels after approximately one year [
         <a href="#rid96">
          96,97
         </a>
         ]. In a retrospective study of 177 patients with HNC treated with either surgery or primary radiation therapy, those with non-HPV associated HNC had worse overall QOL at baseline, 6 months posttreatment, and &gt;1 year posttreatment compared with those with HPV associated HNC [
         <a href="#rid96">
          96
         </a>
         ]. Among those with HPV associated OPC, treatment modality did not impact QOL, symptom, or functional outcomes. Given the increased comorbidities in the non-HPV associated HNC population, these findings are not unexpected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment deintensification and QOL
         </strong>
         – Data suggest that treatment deintensification is associated with improved QOL in patients with HPV associated HNC [
         <a href="#rid98">
          98,99
         </a>
         ]. In these studies, QOL, symptom burden, and functional outcome assessment are critical components of trial design [
         <a href="#rid98">
          98
         </a>
         ]. Treatment deintensification in patients with HPV associated HNC remains an investigational approach and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/115014.html" rel="external">
          "Treatment of human papillomavirus associated oropharyngeal cancer", section on 'Is there a role for treatment deintensification?'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H559186753">
         <span class="h1">
          INABILITY TO WORK AND FINANCIAL DISTRESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment for HNC may have a prolonged debilitating effect on a patient's functional status, thus limiting his/her ability to work during and after treatment. In a cross-sectional study examining work-related disability among patients with HNC, 52 percent of those who were employed at the time of diagnosis were unable to return to work after treatment was completed [
         <a href="#rid100">
          100
         </a>
         ]. Those who were unable to return to work had worse global adaptation in the domains of work and psychological distress [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3320825450">
         <span class="h1">
          CAREGIVERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Caregivers of patients with head and neck cancer often view the patients' QOL more negatively than the patients themselves, which can increase caregiver psychosocial distress [
         <a href="#rid101">
          101
         </a>
         ]. Patients who needed a caregiver also reported lower QOL than those who did not need a caregiver. In addition, patients with increased functional and physical impairments can result in overload of the caregiver, which can in turn negatively impact patients' QOL [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         Interventions that can improve QOL for caregivers include assessing for caregiver distress and facilitating communication between the caregiver, patient, and treatment team [
         <a href="#rid101">
          101
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/96044.html" rel="external">
          "Overview of psychosocial issues in the adult cancer survivor", section on 'Caregivers'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H559186759">
         <span class="h1">
          IMPACT OF TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H559186766">
         <span class="h2">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         For early stage disease, patients may be treated with curative intent using surgery alone and attain high long-term QOL [
         <a href="#rid102">
          102
         </a>
         ]. However, more extensive surgery for HNC can cause symptoms or functional deficits that result in decreased QOL. Common surgery-associated adverse outcomes include lymphedema and fibrosis, disfigurement, voice loss, difficulty with chewing or swallowing, drooling, and neurologic dysfunction. Upfront neck dissection is also associated with more severe dysphagia as measured by patient and physician scores, and swallowing videofluoroscopy [
         <a href="#rid103">
          103
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">
          "Management and prevention of complications during initial treatment of head and neck cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment"
         </a>
         .)
        </p>
        <p>
         Patients often express particular concern or fear of laryngectomy. Laryngectomy is clearly associated with increased symptom control and functional issues; however, long-term QOL is not decreased after total laryngectomy [
         <a href="#rid73">
          73-75
         </a>
         ]. This is likely due to adaptation of expectations with the reality faced by the patient, as well as cognitive behaviors such as benefit finding (see
         <a class="local">
          'Functional performance and QOL'
         </a>
         above). There is no statistical difference in QOL between horizontal supraglottic laryngectomy and partial vertical surgery, although horizontal surgery has better voice quality [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H174560">
         <span class="h2">
          Radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intensity-modulated radiation therapy (IMRT) is standard of care for HNC due to conformal dose distribution with improved sparing of normal tissue [
         <a href="#rid90">
          90,102,104,105
         </a>
         ]. One study reported over 80 percent of five-year survivors being satisfied with their QOL, highlighting the ability of IMRT to preserve long-term functioning [
         <a href="#rid106">
          106
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/89528.html" rel="external">
          "Radiation therapy techniques in cancer treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3406.html" rel="external">
          "General principles of radiation therapy for head and neck cancer", section on 'Intensity-modulated RT'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3409.html" rel="external">
          "Definitive radiation therapy for head and neck cancer: Dose and fractionation considerations"
         </a>
         .)
        </p>
        <p>
         The prominent long-term adverse local effects of radiation therapy are hyposalivation and taste changes. The former may lead to adverse oral health outcomes, including radiation caries, periodontal disease, and osteoradionecrosis. Radiation may also cause lymphedema and fibrosis, which leads to long-term issues with jaw, neck, and shoulder range of motion and swallowing. The addition of concurrent chemotherapy exacerbates all of these side effects. If severe, symptoms and functional deficits may adversely impact overall QOL. The acute and long-term complications of radiation therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">
          "Management and prevention of complications during initial treatment of head and neck cancer"
         </a>
         .)
        </p>
        <p>
         When radiation is used in the postoperative setting, acute and late effects tend to escalate. The adverse soft tissue toxicity of combined surgery and radiation may be severe. In one study, adjuvant radiation therapy after laryngeal surgery was the most powerful correlative with adverse outcomes in a multivariate analysis [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
         The acute and late effects of radiation therapy may manifest differently based on the primary site. For example, laryngeal cancers are more likely to report issues with speech and taste compared with other sites [
         <a href="#rid7">
          7,56,93
         </a>
         ]. Cancers of the larynx are less likely to experience severe pain and have a higher probability of improvement in global QOL at one year compared with oral and pharyngeal cancers [
         <a href="#rid7">
          7,90,107
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H559186780">
         <span class="h2">
          Chemoradiation as primary therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data comparing surgery plus adjuvant radiation with chemoradiation (CRT) as primary therapy have failed to demonstrate a major overall QOL advantage for either treatment modality. For example, studies have reported similar long-term QOL for patients with advanced carcinoma of the larynx whether they underwent total laryngectomy or received concurrent CRT for organ conservation [
         <a href="#rid107">
          107,108
         </a>
         ]. A study of oral cavity squamous cell carcinoma showed no difference in overall health-related QOL (HRQOL) between primary CRT and surgery (with or without adjuvant treatment), with both groups providing acceptable HRQOL [
         <a href="#rid109">
          109
         </a>
         ]. With regards to induction therapy versus concurrent CRT, the European Organisation for Research and Treatment of Cancer (EORTC) 24954 phase III randomized controlled trial comparing combined chemotherapy with sequential induction chemotherapy and RT versus alternating CRT showed a trend towards worse scores in the alternating therapy arm. HRQOL returned to baseline for the majority of patients [
         <a href="#rid110">
          110
         </a>
         ]. Once again, it is important to distinguish QOL for symptoms and functional deficits; differing treatment regimens, while resulting in similar overall QOL, may cause very different acute and late toxicities.
        </p>
        <p class="headingAnchor" id="H3908626444">
         <span class="h2">
          Immunotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient-reported outcomes (PROs) were assessed as an exploratory endpoint in the CheckMate 141 phase III trial for platinum-refractory recurrent or metastatic HNC, in which patients were randomly assigned to either
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         (3 mg/kg every two weeks) or a single-agent investigator's choice of therapy (
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         , or
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         ) [
         <a href="#rid111">
          111
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3380.html" rel="external">
          "Overview of treatment for head and neck cancer"
         </a>
         .)
        </p>
        <p>
         Using the EORTC Quality of Life Questionnaire (QLQ)-30 and EORTC QLQ Head and Neck 35, no clinically meaningful deterioration in QOL was noted in the
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         treatment group as compared with the chemotherapy group, in which 8 of 15 domains showed a deterioration. The three-level European Quality of Life-5 Dimensions (EQ-5D) questionnaire showed clinically meaningful improvement using nivolumab as opposed to clinically meaningful deterioration in the chemotherapy group [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H559186786">
         <span class="h2">
          Feeding tubes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of patients receiving CRT for locally advanced disease experience significant loss of weight and muscle mass, with resultant sarcopenia.
        </p>
        <p>
         The role of prophylactic placement of feeding tubes is controversial and data are mixed. One randomized study showed significantly higher QOL scores (EORTC) in the group receiving prophylactic gastrostomy [
         <a href="#rid112">
          112
         </a>
         ]. However, some argue that prophylactic feeding tube placement leads to disuse of swallowing muscles and, ultimately, higher rates of feeding tube dependence. The importance of these issues led to the development of a specific instrument that measures the impact of enteral feeding tubes on the QOL of these patients [
         <a href="#rid113">
          113
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">
          "The role of parenteral and enteral/oral nutritional support in patients with cancer", section on 'Head and neck cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H460349896">
         <span class="h1">
          REHABILITATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data suggest that patients with HNC benefit from referral to a variety of specialists who can assist in symptom control and function recovery. These include speech and swallow therapy, physical therapy, occupational therapy, lymphedema therapy, audiologists, ophthalmologists, pain control specialists, nutritionists, gastroenterologists, and psychologists. Further studies are required to determine the impact of many of these services on overall long-term QOL.
        </p>
        <p>
         As examples, in a randomized controlled trial of 148 patients with HNC undergoing chemoradiation (CRT), an 11-week structured exercise program improved QOL and functional capacity and prevented worsening of fatigue compared with standard physical activity recommendations [
         <a href="#rid114">
          114
         </a>
         ]. In another randomized controlled nutrition intervention trial, "Eating as Treatment" (EAT), resulted in improved QOL, less depression, and fewer treatment interruptions [
         <a href="#rid115">
          115
         </a>
         ]. Rehabilitation, when used in combination in a systematic manner to maximize effect, has also been demonstrated to improve overall QOL [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
         Further details on available rehabilitation services for patients with HNC are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3394.html" rel="external">
          "Alaryngeal speech rehabilitation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3368.html" rel="external">
          "Speech and swallowing rehabilitation of the patient with head and neck cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2933007042">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">
          "Society guideline links: Head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3581461269">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83256.html" rel="external">
          "Patient education: Throat cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H559186792">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions
         </strong>
         – Health-related quality of life (QOL) incorporates several dimensions (physical, functional, social, psychological) and is subjective, based upon the patient's perception of his/her illness and disability. QOL requires multiple assessments over time to judge the impact of interventions. (See
         <a class="local">
          'Definition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Significant of QOL
         </strong>
         – The importance of QOL has been increasingly recognized and is reflected in its use as an outcome measure in cancer research, on par with response rate and survival. There are, however, continued challenges in the field of head and neck cancer (HNC) QOL research. (See
         <a class="local">
          'Significance of QOL measures in head and neck cancer'
         </a>
         above and
         <a class="local">
          'Pitfalls and limitations of QOL research'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Measures
         </strong>
         – Various instruments are available to assess QOL. These include some that are available for cancer patients in general, as well as a number of validated tools that were specifically designed for use in patients with HNC. Selection of the appropriate QOL instrument should be guided by the correct clinical or research question  (
         <a class="graphic graphic_table graphicRef96171" href="/z/d/graphic/96171.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Patient-reported outcome measures: where do QOL instruments fit in?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Factors associated with QOL
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          QOL and survival
         </strong>
         – Health-related QOL scores were shown to be associated with survival. (See
         <a class="local">
          'QOL and survival'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptom burden
         </strong>
         – Physical and psychosocial issues affect QOL. Awareness of symptom burden can prompt early palliative intervention and/or referral to rehabilitation. (See
         <a class="local">
          'Specific symptoms and their effect on QOL'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tumor-related factors
         </strong>
         – Certain tumor related-factors (eg, disease site, tumor stage, and HPV status) may impact QOL in patients with HNC. (See
         <a class="local">
          'Tumor-related factors and their effect on QOL'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment
         </strong>
         – In addition to the cancer itself, the modalities used to treat disease (eg, surgery, radiation therapy, systemic therapy) are all associated with significant complications and/or toxicities that can have an important impact on QOL. A full consideration of these issues is necessary in managing patients with HNC. (See
         <a class="local">
          'Impact of treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H94740618">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Jonas A de Souza, MD, and Marcy A List, PhD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Murphy BA, Ridner S, Wells N, Dietrich M. Quality of life research in head and neck cancer: a review of the current state of the science. Crit Rev Oncol Hematol 2007; 62:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy BA. Late treatment effects: reframing the questions. Lancet Oncol 2009; 10:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melo Filho MR, Rocha BA, Pires MB, et al. Quality of life of patients with head and neck cancer. Braz J Otorhinolaryngol 2013; 79:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heutte N, Plisson L, Lange M, et al. Quality of life tools in head and neck oncology. Eur Ann Otorhinolaryngol Head Neck Dis 2014; 131:33.
          </a>
         </li>
         <li class="breakAll">
          WHO Working Groups. Measuring Quality of Life.  Programme on Mental Health, 1997.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morton RP, Izzard ME. Quality-of-life outcomes in head and neck cancer patients. World J Surg 2003; 27:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           So WK, Chan RJ, Chan DN, et al. Quality-of-life among head and neck cancer survivors at one year after treatment--a systematic review. Eur J Cancer 2012; 48:2391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sayed SI, Elmiyeh B, Rhys-Evans P, et al. Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions. Cancer Treat Rev 2009; 35:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cella DF. Quality of life: concepts and definition. J Pain Symptom Manage 1994; 9:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Driessen CML, Groenewoud JMM, de Boer JP, et al. Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial. Support Care Cancer 2018; 26:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Driessen CM, de Boer JP, Gelderblom H, et al. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. Eur J Cancer 2016; 52:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silveira AP, Gonçalves J, Sequeira T, et al. Patient reported outcomes in head and neck cancer: selecting instruments for quality of life integration in clinical protocols. Head Neck Oncol 2010; 2:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tschiesner U, Rogers SN, Harréus U, et al. Content comparison of quality of life questionnaires used in head and neck cancer based on the international classification of functioning, disability and health: a systematic review. Eur Arch Otorhinolaryngol 2008; 265:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanna E, Sherman A, Cash D, et al. Quality of life for patients following total laryngectomy vs chemoradiation for laryngeal preservation. Arch Otolaryngol Head Neck Surg 2004; 130:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           List MA, Ritter-Sterr CA, Baker TM, et al. Longitudinal assessment of quality of life in laryngeal cancer patients. Head Neck 1996; 18:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hertrampf K, Wenz HJ, Lehmann KM, et al. Quality of life of patients with maxillofacial defects after treatment for malignancy. Int J Prosthodont 2004; 17:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedlander P, Caruana S, Singh B, et al. Functional status after primary surgical therapy for squamous cell carcinoma of the base of the tongue. Head Neck 2002; 24:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore GJ, Parsons JT, Mendenhall WM. Quality of life outcomes after primary radiotherapy for squamous cell carcinoma of the base of tongue. Int J Radiat Oncol Biol Phys 1996; 36:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finizia C, Hammerlid E, Westin T, Lindström J. Quality of life and voice in patients with laryngeal carcinoma: a posttreatment comparison of laryngectomy (salvage surgery) versus radiotherapy. Laryngoscope 1998; 108:1566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deleyiannis FW, Weymuller EA Jr, Coltrera MD, Futran N. Quality of life after laryngectomy: are functional disabilities important? Head Neck 1999; 21:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gourin CG, Kaboli KC, Boyce BJ, Burkhead LM. Factors associated with nonparticipation in one-year quality-of-life assessment in patients with head and neck squamous cell carcinoma. Laryngoscope 2010; 120:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Meulen IC, May AM, Koole R, Ros WJG. A Distress Thermometer Intervention for Patients With Head and Neck Cancer . Oncol Nurs Forum 2018; 45:E14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin 2007; 57:278.
          </a>
         </li>
         <li class="breakAll">
          EQ-5D (Euroquol Instruments) https://euroqol.org/eq-5d-instruments/ (Accessed on August 17, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilson BS, Gilson JS, Bergner M, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health 1975; 65:1304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein KD, Denniston M, Baker F, et al. Validation of a modified Rotterdam Symptom Checklist for use with cancer patients in the United States. J Pain Symptom Manage 2003; 26:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganz PA, Schag CA, Lee JJ, Sim MS. The CARES: a generic measure of health-related quality of life for patients with cancer. Qual Life Res 1992; 1:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&amp;N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 2000; 36:1796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitzner MA, Meyers CA, Gelke CK, et al. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995; 75:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers SN, Gwanne S, Lowe D, et al. The addition of mood and anxiety domains to the University of Washington quality of life scale. Head Neck 2002; 24:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjordal K, Ahlner-Elmqvist M, Tollesson E, et al. Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol 1994; 33:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           List MA, D'Antonio LL, Cella DF, et al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer 1996; 77:2294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenthal DI, Mendoza TR, Chambers MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 2007; 29:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooperstein E, Gilbert J, Epstein JB, et al. Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health. Head Neck 2012; 34:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogikyan ND, Sethuraman G. Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice 1999; 13:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen AY, Frankowski R, Bishop-Leone J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg 2001; 127:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roach KE, Budiman-Mak E, Songsiridej N, Lertratanakul Y. Development of a shoulder pain and disability index. Arthritis Care Res 1991; 4:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kazi R, Johnson C, Prasad V, et al. Quality of life outcome measures following partial glossectomy: assessment using the UW-QOL scale. J Cancer Res Ther 2008; 4:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Browman GP, Levine MN, Hodson DI, et al. The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. J Clin Oncol 1993; 11:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trotti A, Johnson DJ, Gwede C, et al. Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI). Int J Radiat Oncol Biol Phys 1998; 42:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pace-Balzan A, Cawood JI, Howell R, et al. The Liverpool Oral Rehabilitation Questionnaire: a pilot study. J Oral Rehabil 2004; 31:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aynehchi BB, Obourn C, Sundaram K, et al. Validation of the Modified Brief Fatigue Inventory in head and neck cancer patients. Otolaryngol Head Neck Surg 2013; 148:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathias SD, Crosby RD, Qian Y, et al. Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol 2011; 9:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009; 7:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Østhus AA, Aarstad AK, Olofsson J, Aarstad HJ. Prediction of survival by pretreatment health-related quality-of-life scores in a prospective cohort of patients with head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2013; 139:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karvonen-Gutierrez CA, Ronis DL, Fowler KE, et al. Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol 2008; 26:2754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aarstad HJ, Osthus AA, Olofsson J, Aarstad AK. Level of distress predicts subsequent survival in successfully treated head and neck cancer patients: a prospective cohort study. Acta Otolaryngol 2014; 134:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 2008; 67:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kao SC, Vardy J, Harvie R, et al. Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer 2013; 21:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correia M, Cravo M, Marques-Vidal P, et al. Serum concentrations of TNF-alpha as a surrogate marker for malnutrition and worse quality of life in patients with gastric cancer. Clin Nutr 2007; 26:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehanna HM, Morton RP. Deterioration in quality-of-life of late (10-year) survivors of head and neck cancer. Clin Otolaryngol 2006; 31:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oskam IM, Verdonck-de Leeuw IM, Aaronson NK, et al. Quality of life as predictor of survival: a prospective study on patients treated with combined surgery and radiotherapy for advanced oral and oropharyngeal cancer. Radiother Oncol 2010; 97:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laraway DC, Lakshmiah R, Lowe D, et al. Quality of life in older people with oral cancer. Br J Oral Maxillofac Surg 2012; 50:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrell JE, Ronis DL, Fowler KE, et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verdonck-de Leeuw IM, Buffart LM, Heymans MW, et al. The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: a prospective cohort study. Radiother Oncol 2014; 110:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langius JA, van Dijk AM, Doornaert P, et al. More than 10% weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life. Nutr Cancer 2013; 65:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ronis DL, Duffy SA, Fowler KE, et al. Changes in quality of life over 1 year in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2008; 134:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egestad H, Emaus N. Changes in health related quality of life in women and men undergoing radiation treatment for head and neck cancer and the impact of smoking status in the radiation treatment period. Eur J Oncol Nurs 2014; 18:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Funk GF, Karnell LH, Christensen AJ. Long-term health-related quality of life in survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg 2012; 138:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin BM, Starmer HM, Gourin CG. The relationship between depressive symptoms, quality of life, and swallowing function in head and neck cancer patients 1 year after definitive therapy. Laryngoscope 2012; 122:1518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson TL, Pagedar NA, Karnell LH, Funk GF. Factors associated with mortality in 2-year survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg 2011; 137:1100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fingeret MC, Vidrine DJ, Reece GP, et al. Multidimensional analysis of body image concerns among newly diagnosed patients with oral cavity cancer. Head Neck 2010; 32:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fingeret MC, Hutcheson KA, Jensen K, et al. Associations among speech, eating, and body image concerns for surgical patients with head and neck cancer. Head Neck 2013; 35:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vickery LE, Latchford G, Hewison J, et al. The impact of head and neck cancer and facial disfigurement on the quality of life of patients and their partners. Head Neck 2003; 25:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katre C, Johnson IA, Humphris GM, et al. Assessment of problems with appearance, following surgery for oral and oro-pharyngeal cancer using the University of Washington appearance domain and the Derriford appearance scale. Oral Oncol 2008; 44:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramírez MJ, Ferriol EE, Doménech FG, et al. Psychosocial adjustment in patients surgically treated for laryngeal cancer. Otolaryngol Head Neck Surg 2003; 129:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhardwaj T. Quality of Life of Head and Neck Cancer Patients: Psychosocial Perspective using Mixed Method Approach. Indian J Palliat Care 2021; 27:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delalibera D, Carvalho ACR, Thesolim BL, Rezende LF. Quality of Life of the Patient with Head and Neck Cancer Submitted to Radiotherapy and the Overload of Their Caregivers. Int Arch Otorhinolaryngol 2021; 25:e536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer J, Hipp M, Schäfer C, Kölbl O. Dysphagia. Impact on quality of life after radio(chemo)therapy of head and neck cancer. Strahlenther Onkol 2011; 187:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deng J, Murphy BA, Dietrich MS, et al. Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life. Head Neck 2013; 35:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodard TD, Oplatek A, Petruzzelli GJ. Life after total laryngectomy: a measure of long-term survival, function, and quality of life. Arch Otolaryngol Head Neck Surg 2007; 133:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schindler A, Mozzanica F, Ginocchio D, et al. Voice-related quality of life in patients after total and partial laryngectomy. Auris Nasus Larynx 2012; 39:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vilaseca I, Chen AY, Backscheider AG. Long-term quality of life after total laryngectomy. Head Neck 2006; 28:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakoei S, Haghdoost AA, Rad M, et al. Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients. Arch Iran Med 2012; 15:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolnick L, Deng J, Epstein JB, et al. Associations of oral health items of the Vanderbilt Head and Neck Symptom Survey with a dental health assessment. Oral Oncol 2014; 50:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Low CA, Kalinski P, Bovbjerg DH. Neurocognitive Impairment as One Facet of Cancer-Related Sickness Behavior Symptoms. J Natl Cancer Inst 2015; 107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy BA, Wulff-Burchfield E, Ghiam M, et al. Chronic Systemic Symptoms in Head and Neck Cancer Patients. J Natl Cancer Inst Monogr 2019; 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noel CW, Sutradhar R, Zhao H, et al. Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer: A Longitudinal Population-Based Study. J Clin Oncol 2021; 39:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yunus MB. Editorial review: an update on central sensitivity syndromes and the issues of nosology and psychobiology. Curr Rheumatol Rev 2015; 11:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avelar JMP, Nicolussi AC, Toneti BF, et al. Fatigue in patients with head and neck cancer undergoing radiation therapy: a prospective study. Rev Lat Am Enfermagem 2019; 27:e3168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wulff-Burchfield E, Dietrich MS, Ridner S, Murphy BA. Late systemic symptoms in head and neck cancer survivors. Support Care Cancer 2019; 27:2893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess CB, Rash DL, Daly ME, et al. Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy. JAMA Otolaryngol Head Neck Surg 2014; 140:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwon M, Roh JL, Song J, et al. Noncancer health events as a leading cause of competing mortality in advanced head and neck cancer. Ann Oncol 2014; 25:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324:1685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrell JE, Fisher SG, Wolf GT. Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg 1998; 124:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oskam IM, Verdonck-de Leeuw IM, Aaronson NK, et al. Prospective evaluation of health-related quality of life in long-term oral and oropharyngeal cancer survivors and the perceived need for supportive care. Oral Oncol 2013; 49:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman AC, Simonton S. Advances in quality of life research among head and neck cancer patients. Curr Oncol Rep 2010; 12:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wan Leung S, Lee TF, Chien CY, et al. Health-related quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&amp;N35 questionnaires. BMC Cancer 2011; 11:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin YL, Lin IC, Liou JC. Symptom patterns of patients with head and neck cancer in a palliative care unit. J Palliat Med 2011; 14:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahalingam S, Spielmann P. Quality of Life Outcomes following Treatment of Hypopharyngeal Cancer. Adv Otorhinolaryngol 2019; 83:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bindewald J, Oeken J, Wollbrueck D, et al. Quality of life correlates after surgery for laryngeal carcinoma. Laryngoscope 2007; 117:1770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjordal K, Ahlner-Elmqvist M, Hammerlid E, et al. A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data. Laryngoscope 2001; 111:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammerlid E, Silander E, Hörnestam L, Sullivan M. Health-related quality of life three years after diagnosis of head and neck cancer--a longitudinal study. Head Neck 2001; 23:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maxwell JH, Mehta V, Wang H, et al. Quality of life in head and neck cancer patients: impact of HPV and primary treatment modality. Laryngoscope 2014; 124:1592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Høxbroe Michaelsen S, Grønhøj C, Høxbroe Michaelsen J, et al. Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients. Eur J Cancer 2017; 78:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marur S, Li S, Cmelak AJ, et al. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol 2016; :JCO2016683300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearlstein KA, Wang K, Amdur RJ, et al. Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2019; 103:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor JC, Terrell JE, Ronis DL, et al. Disability in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kassir ZM, Li J, Harrison C, et al. Disparity of perception of quality of life between head and neck cancer patients and caregivers. BMC Cancer 2021; 21:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broglie MA, Soltermann A, Haile SR, et al. Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16-positivity. Laryngoscope 2013; 123:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deschuymer S, Nevens D, Duprez F, et al. Clinical factors impacting on late dysphagia following radiotherapy in patients with head and neck cancer. Br J Radiol 2018; 91:20180155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marucci L, Marzi S, Sperduti I, et al. Influence of intensity-modulated radiation therapy technique on xerostomia and related quality of life in patients treated with intensity-modulated radiation therapy for nasopharyngeal cancer. Head Neck 2012; 34:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rathod S, Gupta T, Ghosh-Laskar S, et al. Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study. Oral Oncol 2013; 49:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen AM, Daly ME, Farwell DG, et al. Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy. JAMA Otolaryngol Head Neck Surg 2014; 140:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guibert M, Lepage B, Woisard V, et al. Quality of life in patients treated for advanced hypopharyngeal or laryngeal cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2011; 128:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trivedi NP, Swaminathan DK, Thankappan K, et al. Comparison of quality of life in advanced laryngeal cancer patients after concurrent chemoradiotherapy vs total laryngectomy. Otolaryngol Head Neck Surg 2008; 139:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crombie AK, Farah CS, Batstone MD. Health-related quality of life of patients treated with primary chemoradiotherapy for oral cavity squamous cell carcinoma: a comparison with surgery. Br J Oral Maxillofac Surg 2014; 52:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bottomley A, Tridello G, Coens C, et al. An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group. Cancer 2014; 120:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 2017; 18:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salas S, Baumstarck-Barrau K, Alfonsi M, et al. Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: Prospective randomized trial. Radiother Oncol 2009; 93:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens CS, Lemon B, Lockwood GA, et al. The development and validation of a quality-of-life questionnaire for head and neck cancer patients with enteral feeding tubes: the QOL-EF. Support Care Cancer 2011; 19:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuel SR, Maiya AG, Fernandes DJ, et al. Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemo-radiotherapy. Support Care Cancer 2019; 27:3913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Britton B, Baker AL, Wolfenden L, et al. Eating As Treatment (EAT): A Stepped-Wedge, Randomized Controlled Trial of a Health Behavior Change Intervention Provided by Dietitians to Improve Nutrition in Patients With Head and Neck Cancer Undergoing Radiation Therapy (TROG 12.03). Int J Radiat Oncol Biol Phys 2019; 103:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passchier E, Stuiver MM, van der Molen L, et al. Feasibility and impact of a dedicated multidisciplinary rehabilitation program on health-related quality of life in advanced head and neck cancer patients. Eur Arch Otorhinolaryngol 2016; 273:1577.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3369 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17408963" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Quality of life research in head and neck cancer: a review of the current state of the science.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19482238" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Late treatment effects: reframing the questions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23503912" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Quality of life of patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24291153" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Quality of life tools in head and neck oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24291153" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Quality of life tools in head and neck oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14509523" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Quality-of-life outcomes in head and neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22579456" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Quality-of-life among head and neck cancer survivors at one year after treatment--a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19375235" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8014530" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Quality of life: concepts and definition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29230548" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26655558" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21040524" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Patient reported outcomes in head and neck cancer: selecting instruments for quality of life integration in clinical protocols.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18392633" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Content comparison of quality of life questionnaires used in head and neck cancer based on the international classification of functioning, disability and health: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15262766" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Quality of life for patients following total laryngectomy vs chemoradiation for laryngeal preservation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8774916" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Longitudinal assessment of quality of life in laryngeal cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15686093" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Quality of life of patients with maxillofacial defects after treatment for malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11891940" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Functional status after primary surgical therapy for squamous cell carcinoma of the base of the tongue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8892459" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Quality of life outcomes after primary radiotherapy for squamous cell carcinoma of the base of tongue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9778303" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Quality of life and voice in patients with laryngeal carcinoma: a posttreatment comparison of laryngectomy (salvage surgery) versus radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10376751" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Quality of life after laryngectomy: are functional disabilities important?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20564472" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Factors associated with nonparticipation in one-year quality-of-life assessment in patients with head and neck squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29251296" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A Distress Thermometer Intervention for Patients With Head and Neck Cancer .
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17855485" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Patient-reported outcomes in cancer: a review of recent research and policy initiatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17855485" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Patient-reported outcomes in cancer: a review of recent research and policy initiatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9817107" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1200192" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The sickness impact profile. Development of an outcome measure of health care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14585549" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Validation of a modified Rotterdam Symptom Checklist for use with cancer patients in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1301111" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The CARES: a generic measure of health-related quality of life for patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10974628" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&amp;N35) in head and neck patients. EORTC Quality of Life Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7850714" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12112548" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The addition of mood and anxiety domains to the University of Washington quality of life scale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7818919" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8635098" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17358040" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22127786" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10622521" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Validation of an instrument to measure voice-related quality of life (V-RQOL).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11448365" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11395238" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11188601" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Development of a shoulder pain and disability index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18923203" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Quality of life outcome measures following partial glossectomy: assessment using the UW-QOL scale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8487051" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9788402" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15189321" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The Liverpool Oral Rehabilitation Questionnaire: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22972874" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Validation of the Modified Brief Fatigue Inventory in head and neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21542414" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20030832" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23329087" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Prediction of survival by pretreatment health-related quality-of-life scores in a prospective cohort of patients with head and neck squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18509185" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Quality of life scores predict survival among patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24256042" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Level of distress predicts subsequent survival in successfully treated head and neck cancer patients: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18452641" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22936495" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17949861" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Serum concentrations of TNF-alpha as a surrogate marker for malnutrition and worse quality of life in patients with gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16759240" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Deterioration in quality-of-life of late (10-year) survivors of head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20189668" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Quality of life as predictor of survival: a prospective study on patients treated with combined surgery and radiotherapy for advanced oral and oropharyngeal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22326324" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Quality of life in older people with oral cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15096421" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Clinical predictors of quality of life in patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24582144" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23368916" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : More than 10% weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18347247" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Changes in quality of life over 1 year in patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24877857" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Changes in health related quality of life in women and men undergoing radiation treatment for head and neck cancer and the impact of smoking status in the radiation treatment period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22248560" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Long-term health-related quality of life in survivors of head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22467530" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The relationship between depressive symptoms, quality of life, and swallowing function in head and neck cancer patients 1 year after definitive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22106233" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Factors associated with mortality in 2-year survivors of head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19626634" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Multidimensional analysis of body image concerns among newly diagnosed patients with oral cavity cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22431304" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Associations among speech, eating, and body image concerns for surgical patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12658733" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The impact of head and neck cancer and facial disfigurement on the quality of life of patients and their partners.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18329949" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Assessment of problems with appearance, following surgery for oral and oro-pharyngeal cancer using the University of Washington appearance domain and the Derriford appearance scale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12869923" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Psychosocial adjustment in patients surgically treated for laryngeal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34511799" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Quality of Life of Head and Neck Cancer Patients: Psychosocial Perspective using Mixed Method Approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34765029" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Quality of Life of the Patient with Head and Neck Cancer Submitted to Radiotherapy and the Overload of Their Caregivers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22037655" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Dysphagia. Impact on quality of life after radio(chemo)therapy of head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22791550" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17576901" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Life after total laryngectomy: a measure of long-term survival, function, and quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21592703" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Voice-related quality of life in patients after total and partial laryngectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16200627" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Long-term quality of life after total laryngectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22424038" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24239279" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Associations of oral health items of the Vanderbilt Head and Neck Symptom Survey with a dental health assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26101332" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Neurocognitive Impairment as One Facet of Cancer-Related Sickness Behavior Symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31425597" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Chronic Systemic Symptoms in Head and Neck Cancer Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33405964" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer: A Longitudinal Population-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26138918" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Editorial review: an update on central sensitivity syndromes and the issues of nosology and psychobiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31432921" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Fatigue in patients with head and neck cancer undergoing radiation therapy: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30554277" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Late systemic symptoms in head and neck cancer survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24526276" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24669018" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Noncancer health events as a leading cause of competing mortality in advanced head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2034244" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738804" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23318122" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Prospective evaluation of health-related quality of life in long-term oral and oropharyngeal cancer survivors and the perceived need for supportive care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20425081" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Advances in quality of life research among head and neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21486431" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Health-related quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&amp;N35 questionnaires.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21413849" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Symptom patterns of patients with head and neck cancer in a palliative care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30943471" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Quality of Life Outcomes following Treatment of Hypopharyngeal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17906497" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Quality of life correlates after surgery for laryngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568582" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11303628" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Health-related quality of life three years after diagnosis of head and neck cancer--a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24353066" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Quality of life in head and neck cancer patients: impact of HPV and primary treatment modality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28431302" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28029303" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30395903" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15210560" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Disability in patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34670507" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Disparity of perception of quality of life between head and neck cancer patients and caregivers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23154864" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16-positivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29668302" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Clinical factors impacting on late dysphagia following radiotherapy in patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21400632" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Influence of intensity-modulated radiation therapy technique on xerostomia and related quality of life in patients treated with intensity-modulated radiation therapy for nasopharyngeal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23562564" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24337483" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21613002" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Quality of life in patients treated for advanced hypopharyngeal or laryngeal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18984267" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Comparison of quality of life in advanced laryngeal cancer patients after concurrent chemoradiotherapy vs total laryngectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24148700" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Health-related quality of life of patients treated with primary chemoradiotherapy for oral cavity squamous cell carcinoma: a comparison with surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24452673" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28651929" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19524315" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: Prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20574664" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : The development and validation of a quality-of-life questionnaire for head and neck cancer patients with enteral feeding tubes: the QOL-EF.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30919154" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemo-radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30296472" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Eating As Treatment (EAT): A Stepped-Wedge, Randomized Controlled Trial of a Health Behavior Change Intervention Provided by Dietitians to Improve Nutrition in Patients With Head and Neck Cancer Undergoing Radiation Therapy (TROG 12.03).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26024692" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Feasibility and impact of a dedicated multidisciplinary rehabilitation program on health-related quality of life in advanced head and neck cancer patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
